Exelixis, Inc. (EX9.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
As of 08:15AM CEST. Market open.
| Previous Close | 19.17 |
| Open | 19.28 |
| Bid | 18.75 x 90000 |
| Ask | 18.91 x 90000 |
| Day's Range | 19.28 - 19.28 |
| 52 Week Range | 17.00 - 22.00 |
| Volume | |
| Avg. Volume | 63 |
| Market Cap | 5.668B |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | 32.13 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
Exelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic versions of Cabometyx in the United States beginning January 2031.
- Zacks
Exelixis (EXEL) International Revenue Performance Explored
Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
- Insider Monkey
Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript
Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript April 30, 2024 Exelixis, Inc. misses on earnings expectations. Reported EPS is $0.17 EPS, expectations were $0.28. EXEL isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, ladies and gentlemen, and […]
© 2024 Yahoo. All rights reserved.